No animal-derived ligands: How is the 'safety lock' of biopharmaceuticals made?

The safety chain in biopharmaceuticals consists of hundreds or even thousands of steps. Among them, there's one seemingly insignificant yet critically important link—the layer of ligands on the affinity chromatography resin that are responsible for "capturing" the target protein.

Where these ligands come from directly affects the safety level of the entire production line.

If the ligand production process involves fetal bovine serum, animal-derived trypsin, or even direct extraction from animal tissues, then the risk of viral contamination, prion contamination, and batch-to-batch quality variations always hang overhead like the sword of Damocles. On the other hand, if the entire production chain—from gene sequence to final product—does not involve any animal-derived components, the risks coming from animal sources can be fundamentally eliminated.

This is the core value of animal-free ligands—not just "a bit safer," but a complete reconstruction of safety logic from the source.

1. What are animal-free ligands?

Let's break down the terms first.

A ligand, in the context of chromatography resin, is the "molecular grabber" attached to the surface of resin beads that can specifically capture the target protein. For example, Protein A, which is most commonly used in antibody purification, is a ligand—it tightly binds to the Fc region of antibodies and lets other unwanted proteins flow through, achieving single-step purification.

Animal-free means that the entire production process and all materials for this ligand do not come from any animal tissues or animal cells.

You might ask: isn’t Protein A a protein from Staphylococcus aureus? And bacteria aren’t animals, so isn’t it already animal-free?

The issue isn’t that simple. Traditional ligand production, even if the protein itself is expressed by microorganisms, often uses animal-derived components—like fetal bovine serum in the cell culture medium, animal-derived enzymes during purification, or even ligands directly extracted from animal tissues. These animal-derived components are the "hidden risks" in biopharmaceuticals.

So genuinely animal-free ligands have a strict definition: from the gene sequence, expression system, culture medium, and purification reagents to the final product, no animal-derived components are used, and no animal-origin raw materials or process aids are involved. Simply put: from DNA to final product, there’s zero contact with anything animal.

2. Why go "animal-free"? How big are the risks from animal sources?

Risks Posed by Animal-derived Raw Materials

The safety requirements for biopharmaceuticals are several orders of magnitude higher than for the food industry. Because drugs go directly into human veins, even a tiny bit of contamination can lead to disaster. The risks brought by animal-derived components mainly fall into three categories:

Risk 1: Viral contamination — an invisible "time bomb"

This is the deadliest risk. Animal-derived raw materials may carry various viruses — bovine materials might carry BVDV (Bovine Viral Diarrhea Virus), porcine materials could have porcine parvovirus, and murine materials may carry murine leukemia virus. Once these viruses enter the drugs through the production process, the consequences could be catastrophic. This is why the ICH Q5A guidelines clearly require that biotech products undergo viral safety evaluation. With animal-free ligands, this risk is cut off at the source — no animal-derived materials are used in the production chain, eliminating the possibility of introducing animal viruses from the start.

Risk 2: Prions — the ghost of "mad cow disease"

Even scarier than viruses are prions, misfolded proteins that can misfold normal proteins as well, causing spongiform encephalopathy — what we know as "mad cow disease." The tricky part is that prions are extremely resistant to conventional heat, UV light, ethanol/formaldehyde disinfectants, and the extreme conditions needed to fully inactivate them (strong bases, ultra-high temperatures) would also destroy the ligand's protein activity. So they can’t be removed through processing and must be avoided entirely by not using animal-derived materials from the outset. After the mad cow disease outbreak in the UK in the 1990s, global vigilance regarding bovine materials reached its peak. Animal-free ligands completely bypass this issue.

Risk 3: Batch-to-batch variation and quality fluctuations

Even putting safety risks aside, the quality variability of animal-derived components is a headache. Different batches of serum have varying protein content, activity, and impurity profiles. This batch-to-batch variation can affect the entire production process. Animal-free ligands are produced using engineered microbes in fully chemically defined media, with precisely controlled composition, greatly improving batch consistency.

To put it simply: animal-derived ligands are like buying fresh produce from different local markets, where quality can fluctuate; animal-free ligands are like standardized factory-made preproducts, with composition and specifications highly uniform in every batch.

3. Technical Approaches for Animal-Free Ligands: From Recombinant Modification to De Novo Design

"Animal-free" is a set of techniques that "bypass animals and build ligands in vitro." There are three main approaches, each at a different stage of technological maturity.

Path 1: Recombinant Microbial Ligands — The 'De-Animalization' of Classic Ligands

The earliest animal-free ligands were basically classic affinity ligands 'relocated' — from being sourced naturally or expressed in animal cells to recombinant expression in microbes. The most typical examples are recombinant Protein A, as well as Protein G and Protein L, all basically expressed in E. coli. The culture medium is chemically defined, achieving fully animal-free production. This generation of ligands is versatile and low-cost but can only bind to specific types of proteins.

Path 2: In Vitro Display Libraries — Putting an 'Antibody Library' in a Test Tube

This is currently the most mature path for discovering animal-free antibodies. Represented by phage display technology, it involves constructing phage libraries with tens of billions of human antibody sequences and enriching high-affinity binders from a vast pool of candidates. This method can be entirely based on human antibody sequences, avoiding the immunogenicity issues of mouse-derived antibodies, and the screening conditions can be precisely controlled in vitro. Selecting single-domain antibody ligands using synthetic phage libraries falls under this path. The whole process requires no immunization in animals and can be completed entirely in vitro.

Path 3: Computational Design — 'Drawing' Ligands on a Computer

This is the fastest-developing route in recent years. Computational tools analyze the binding interface of target proteins and design entirely new binding proteins from scratch. De novo designed mini binding proteins typically have 20–100 amino acids, with a molecular weight of only 4–10 kDa, about 1/15–1/40 that of conventional IgG antibodies. After affinity maturation, their binding strength can reach nM or even pM levels, and their thermal stability is generally better than natural antibody fragments. This method does not rely on any animals or natural protein scaffolds at all, truly achieving 'fully in vitro design.'

Three paths, one common goal: to break away from dependence on the animal immune system and shift ligand discovery from 'in vivo selection' to 'in vitro rational design.'

4. How Are Animal-Free Ligands Made?

Animal-free Manufacturing Process

The three technical paths mentioned above answer the question of 'which methods can be used to find ligands.' But no matter which path you take, the final industrial production must follow a strict animal-free process. This process can be summarized in three steps:

Step 1: Gene sequence design—'de-animalize' from the source

If the initial ligand sequence comes from animal immunity (like camelid VHHs or mouse-derived antibodies), you can directly get qualified raw materials through gene synthesis + animal-free recombinant expression; for ligands used in downstream therapeutic antibody purification, you can also further humanize them to reduce potential immunogenic risks from foreign protein residues. If the ligand comes from microbes (for example, Protein A from Staphylococcus aureus), this step is relatively simple, but codon optimization is still needed to ensure high expression in engineered bacteria.

Step 2: Expression system—produce proteins using 'non-animal hosts'

This is the key step. Mainstream expression systems include E. coli (the classic prokaryotic system, completely animal-free, low cost, high yield, suitable for smaller and simpler ligands) and yeast (a eukaryotic system that can handle more complex protein folding, suitable for ligands with somewhat more complex structures). The key point is that the culture medium must also be animal-free—in high-end biopharma applications, chemically defined media are usually used, with every component and concentration clearly defined.

Step 3: Purification process—no animal-derived reagents at any stage

Once the protein is expressed, it still needs to be purified. Enzymes, chromatography resins, and buffer reagents used during purification all must be animal-free. Missing any step means all previous efforts are wasted. The resulting animal-free ligand must also undergo rigorous testing—to confirm no animal-derived residues are detected, no viruses are detected, and batch consistency meets standards before it can be linked to the resin beads and become an animal-free affinity resin.

5. How can AI accelerate the development of animal-free ligands?

Animal-free ligands are great, but there's one major pain point: development is too hard and too slow. Especially for customized single-domain antibody ligands—building the library, screening, affinity maturation, stability validation, expression optimization—it can easily take six months to a year for the whole process, and the costs aren't cheap.

AI is changing this pace. AI protein design platforms like MatwingsVenus™ are shifting the development of animal-free ligands from 'trial-and-error screening' to 'design-driven'.

5.1. Designing entirely new ligands from scratch—completely skipping animal immunization

Traditionally, developing a new ligand involved either immunizing animals (with the issue of animal origin) or building a large library for screening (inefficient). MatwingsVenus™ can start from the structure of the target protein and design entirely new binding proteins as ligand candidates from scratch—no animals needed, no biological screening library construction required, generating candidate molecules directly in silico and then selecting the most promising ones for experimental validation. More importantly, the whole process from design to expression is animal-free, fully compliant with regulatory requirements from the start.

5.2. Stability engineering—making ligands more durable

Industrial ligands don’t just need strong binding—they need to be stable. Especially for affinity resins, which are washed with strong alkali after each use; if a ligand can't resist alkali, it can deactivate after just a few cycles. MatwingsVenus™ can direct stability modifications on ligand proteins: predicting which mutations improve alkali resistance, which enhance thermal stability, and which combinations extend resin lifetime while maintaining binding activity. For instance, in a project with Kinsei Pharma, Matwings Tech improved the alkali resistance of a regular single-domain antibody fourfold in less than one year and successfully applied it in 5000-liter industrial-scale production.

5.3. Specificity optimization—only grab the protein you want

Purification struggles with non-specific binding—the ligand is supposed to bind just the target protein but ends up sticking to unwanted proteins, lowering purity. MatwingsVenus™ can analyze the ligand-target binding interface, identify key hotspot residues, and optimize the ligand's specificity through site-directed mutations, making it 'grip only one and ignore the rest.' This precision is especially valuable for protein families with highly similar sequences.

5.4. Expression optimization—higher ligand protein yields

Animal-free expression is safe, but sometimes yields are low—microbial systems differ from animal cells, and some proteins just express poorly or form inclusion bodies. MatwingsVenus™ can improve expression and solubility of ligand proteins in microbial systems via codon optimization, solubility prediction, and folding stability modifications, making animal-free production safe and cost-effective.

6. So why is animal-free a 'must-have' in biopharmaceuticals?

Imperative for Biopharmaceuticals

You might think, it's just a ligand, right? Animal-derived ones have been used for decades without problems, do we really need to make such a big deal out of it?

In reality, non-animal-derived options are no longer just a "better" choice—they are a "must-have" trend, driven by three factors:

Regulatory: Requirements are getting stricter. Regulatory agencies around the world are pushing for the "de-animalization" of biopharmaceuticals. While there’s no blanket ban on animal-derived components, companies are required to conduct comprehensive viral safety assessments and risk control for all animal-derived materials—which is a huge compliance cost in itself. If your entire production process is non-animal-derived, the burden of proving safety during regulatory submissions is much lower.

Quality: The need for batch-to-batch consistency. Non-animal-derived ligands have precise components and controllable processes, so their batch-to-batch consistency is far better than animal-derived products. This is extremely valuable for quality control in large-scale production.

Business: The underlying logic of reducing cost and increasing efficiency. On the surface, non-animal-derived ligands might be slightly more expensive per unit than regular ligands, but when you look at the overall costs, they’re actually more cost-effective: lowering virus clearance validation costs, reducing scrap rates due to batch variation, saving time during regulatory submissions, extending filler lifespan, and reducing product recall risks. Meanwhile, high-regulation fields like cell therapy and gene therapy often prioritize non-animal-derived materials during the research and registration phase, creating a hard demand for market access. In biopharma, where one failure can mean huge losses, safety and stability are the biggest cost reducers.

Conclusion

Non-animal-derived ligands might seem like a tiny part of the biopharma supply chain—just a little protein hanging on a filler bead.

But they reflect the whole biopharma industry's evolution from "relying on nature" to "fully controllable." Media have gone from serum-supplemented to chemically defined, trypsin from animal pancreas to recombinant expression, albumin from human plasma to yeast-derived, ligands from animal immunization and extraction to AI-designed from scratch—every step of "de-animalization" adds a safety lock for biopharma’s security and quality.

And with AI, this "safety lock" is no longer an expensive luxury. One day, when the entire biopharma chain is non-animal-derived, fully synthetic, and traceable, every antibody we produce, every vaccine we make, every gene therapy drug we develop can truly be called "safe, controllable, and accessible."

Non-animal-derived ligands are just a small step in this grand journey, but it’s a solid, concrete step.